GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Current Ratio

Strongbridge Biopharma (Strongbridge Biopharma) Current Ratio : 3.00 (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Strongbridge Biopharma's current ratio for the quarter that ended in Jun. 2021 was 3.00.

Strongbridge Biopharma has a current ratio of 3.00. It generally indicates good short-term financial strength.

The historical rank and industry rank for Strongbridge Biopharma's Current Ratio or its related term are showing as below:

SBBP' s Current Ratio Range Over the Past 10 Years
Min: 2.86   Med: 5.15   Max: 10.23
Current: 3

During the past 8 years, Strongbridge Biopharma's highest Current Ratio was 10.23. The lowest was 2.86. And the median was 5.15.

SBBP's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.8 vs SBBP: 3.00

Strongbridge Biopharma Current Ratio Historical Data

The historical data trend for Strongbridge Biopharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Current Ratio Chart

Strongbridge Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Current Ratio
Get a 7-Day Free Trial 4.24 4.87 7.67 3.44 4.37

Strongbridge Biopharma Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.39 4.51 4.37 3.63 3.00

Competitive Comparison of Strongbridge Biopharma's Current Ratio

For the Biotechnology subindustry, Strongbridge Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strongbridge Biopharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Current Ratio falls into.



Strongbridge Biopharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Strongbridge Biopharma's Current Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Current Ratio (A: Dec. 2020 )=Total Current Assets (A: Dec. 2020 )/Total Current Liabilities (A: Dec. 2020 )
=92.352/21.131
=4.37

Strongbridge Biopharma's Current Ratio for the quarter that ended in Jun. 2021 is calculated as

Current Ratio (Q: Jun. 2021 )=Total Current Assets (Q: Jun. 2021 )/Total Current Liabilities (Q: Jun. 2021 )
=70.122/23.382
=3.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strongbridge Biopharma  (NAS:SBBP) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Strongbridge Biopharma Current Ratio Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Executives
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c. 10 percent owner C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner 10 percent owner C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp 10 percent owner 731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson director, officer: Chief Executive Officer DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen director 60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger director 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long officer: Chief Legal Officer C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen officer: Chief Medical Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit officer: Chief Commercial Officer 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz officer: Chief Financial Officer 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender officer: Chief Operating Officer C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380

Strongbridge Biopharma (Strongbridge Biopharma) Headlines

From GuruFocus